<

LAXXON MEDICAL Laxxon Medical to Participate in 26th Annual Needham Growth Conference

Transparency directive : regulatory news

18/12/2023 14:00

Laxxon Medical to Participate in 26th Annual Needham Growth Conference

New York, 12/18/2023 / 08:00, EST/EDT - EQS Newswire - Laxxon Medical


NEW YORK, NY / ACCESSWIRE / December 18, 2023 / Laxxon Medical, a leading pharma-technology company pioneering a new generation of advanced pharmaceuticals, today announced that management is scheduled to participate in the 26th Annual Needham Growth Conference on January 17th and 18th, 2024 in New York City.

Laxxon CEO/Chairman Helmut Kerschbaumer and Chief Strategy Officer Alexander Ruckdaeschel will participate in one-on-one meetings with institutional, private equity, and venture capital investors.

The conference will be held onsite at the Lotte New York Palace in New York City on Wednesday, January 17th, and Thursday, January 18th, with virtual access on Tuesday, January 16th, and Friday, January 19th. For more information about the conference or to schedule a one-on-one meeting with Laxxon Medical, please get in touch with your Needham representative.

About Laxxon Medical
Laxxon Medical is a pharma-technology company pioneering a new generation of advanced pharmaceuticals with SPID®, a novel 3D screen printing platform technology. For new and common pharmaceutical drugs, SPID® unlocks innovative drug delivery advancements paired with fast-tracked market access and extensive IP protection to yield disruptive opportunities for partners and life-changing results for patients.

Laxxon's pipeline includes ongoing working-projects with notable pharma players, biotech companies and research universities, in addition to 13 in-house Advanced Patented Generics products. Laxxon's IP is continuously growing and consists of 150 patents and patent applications with more than 3,000 patent claims.

Laxxon is partnered with CDMO Hovione and is jointly establishing cGMP productions in Portugal and the United States.

Company website: www.laxxonmedical.com.

Investor Contact:
Alexander Ruckdaeschel
Chief Strategy Director
a.ruckdaeschel@laxxonmedical.com

Media Contact:
Frances Hoggard
Communications Manager
f.hoggard@laxxonmedical.com

SOURCE: Laxxon Medical



12/18/2023 EQS Newswire / EQS Group AG



fncls.ssp?fn=show_t_gif&application_id=1798351&application_name=news&site_id=symex

source : webdisclosure.com



Other stories

21/12/2024 08:21
21/12/2024 12:26
21/12/2024 12:24
21/12/2024 12:13
20/12/2024 18:31
20/12/2024 23:24
21/12/2024 06:58
21/12/2024 13:20
21/12/2024 07:45
21/12/2024 05:00
21/12/2024 02:25
21/12/2024 13:04
20/12/2024 18:14
20/12/2024 17:47
21/12/2024 06:05
21/12/2024 09:14
21/12/2024 11:11
21/12/2024 03:03
20/12/2024 13:30
20/12/2024 14:05
20/12/2024 14:03
21/12/2024 12:31
21/12/2024 09:37
21/12/2024 04:49
21/12/2024 06:18
21/12/2024 08:30
21/12/2024 13:01
21/12/2024 10:50
20/12/2024 19:31
21/12/2024 09:04
19/12/2024 16:12
20/12/2024 18:55
21/12/2024 10:18
20/12/2024 15:00
20/12/2024 14:19
21/12/2024 11:00
21/12/2024 13:04
20/12/2024 17:35